RSS | Login | Register

VANTIN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VANTIN to:

Generic Name for VANTIN

Cefpodoxime proxetil 100mg, 200mg; tabs.

Legal Classification:

Pharmacological Class for VANTIN

Cephalosporin.

Manufacturer of VANTIN

Pfizer Labs

Indications for VANTIN

Susceptible mild to moderate infections including acute otitis media, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute community-acquired pneumonia, urinary tract, skin and skin structures; cervical, anorectal (females only) and urethral gonorrhea.

Adult dose for VANTIN

Take tabs with food. ≥13 yrs: Pneumonia: 200mg every 12 hours for 14 days. Bronchitis, sinusitis: 200mg every 12 hours for 10 days. Pharyngitis/tonsillitis: 100mg every 12 hours for 5–10 days. Skin and skin structures: 400mg every 12 hours for 7–14 days. UTI: 100mg every 12 hours for 7 days. Uncomplicated gonorrhea: 200mg once as a single dose. Renal failure or hemodialysis: see literature.

Children's dosing for VANTIN

Use susp. <2 months: not recommended. 2months–12yrs: Acute otitis media: 5mg/kg (max 200mg) every 12 hrs for 5 days. Pharyngitis/tonsillitis: 5mg/kg (max 100mg) every 12 hrs for 5–10 days. Sinusitis: 5mg/kg (max 200mg) every 12 hrs for 10 days.

Also:

VANTIN GRANULES

Precautions for VANTIN

Penicillin or other allergy. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for VANTIN

Antacids, H₂ antagonists, oral anticholinergics may decrease efficacy. Potentiated by probenecid. Avoid concomitant diuretics, other nephrotoxic drugs. May cause false (+) direct Coomb's test.

Adverse Reactions for VANTIN

GI upset, abdominal pain, headache, rash, anaphylaxis.

How is VANTIN supplied?

Tabs—20, 100
Susp—50mL, 75mL, 100mL

Related Disease:

Bronchitis, chronic

Infections, bacterial~systemic antiinfectives

Pneumonia

Sinusitis

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.